SARS-CoV2 Infection, COVID-19, Gut Microbiota, Mucosal Response, Children
Conditions
Brief summary
SARS-CoV-2 is the causative agent of the COVID-19 pandemic. It appears to cause only mild to moderate upper respiratory symptoms in children, in addition to gastrointestinal symptoms resulting from its penetration into intestinal cells. Viral respiratory infections are often accompanied by a change in the composition of the gut microbiota (GM). Additionally, intestinal metabolites and integrity appear to be altered. This work aims to study the composition of the GM of Lebanese children, currently (n=14) and previously (n=33) infected with SARS-CoV-2 and to compare it to pre-pandemic controls (n=39). Furthermore, the correlation between the composition of the GM and the intestinal homeostasis are evaluated. Clinical data and stool samples were collected from children aged 1 month to 12 years. The bacterial profile is determined by quantitative PCR and 16S rRNA sequencing. Levels of secretory immunoglobulin A (sIgA), fecal calprotectin, beta defensin type 2 (hBD-2), short-chain fatty acids (SCFAs), tryptophan derivatives, and bile acids are also evaluated. Given the well-established relationship between the GM and the immune system, the results of this study could serve as a potential basis for the implementation of personalized nutrition and biotic supplementations aimed at restoring the host-microbiota symbiosis, pointing to the prevention and treatment of COVID-19
Interventions
Following the approval of the legal guardians, a stool collection container was given to the parents in order to collect the stools. Stools were kept at 4ºC for 24h max, then transported to the laboratory, aliquoted and stored at -80ºC for further analysis
Sponsors
Saint-Joseph University
Université Paris Cité
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Months to 12 Years
Healthy volunteers
Yes
Inclusion criteria
* Within age limits * positive PCR
Exclusion criteria
* metabolic disorders, hepatic disorders, immunodeficiency, allergy, autoimmune diseases, IBD, food intolerance, antibiotic administration within 3 months, pro and prebiotic administration within 3 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Analysis of the gut microbiota in covid-19 children | june 2024 | Quantify and analyse the composition of the gut microbiota if Lebanese infected Children |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effect on covid infection on mucosal barrier | june 2024 | Evaluation of the consequences of the infection on the mucosal barrier |
| correlation between gut microbiota and mucosal response | september 2024 | examine the correlation between the composition of the gut microbiota and the mucosal response |
Countries
Lebanon
Outcome results
None listed